Jubilant out-licenses BET inhibitors to Checkpoint
In its first out-licensing deal, Jubilant Biosys Ltd. granted Checkpoint Therapeutics Inc. exclusive global rights to patents covering BRD4 inhibitor compounds for cancer; BRD4 is a member of the BET (Bromodomain and Extra Terminal) domain.
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.